Research
Poster
Authors: Shruti Chopra, PhD | Vandana Yadav, MS | Stan Kachnowski, PhD, MPA
In 2009, 96% of all genome-wide association studies were conducted on European-ancestry populations. Fifteen years later, Sub-Saharan African representation in pharmacogenomics stands at 1.6% – unchanged (Corpas et al., Cell Genomics, 2024).
GWAS sample counts have grown exponentially, but almost entirely within European-ancestry cohorts, compounding rather than correcting the imbalance. The consequences span clinical, commercial, and sovereign domains. Over 80% of FDA-approved drugs show reduced efficacy in non-European populations. Enzymes metabolising 70%+ of all prescribed drugs show markedly different allele distributions across ancestries. Women face compounded harm: dosing standards set on male-only data, never corrected by ancestry-specific reference. 4.6 million unique genetic variants – concentrated in African and Indigenous genomes – remain invisible to every existing pharmaceutical pipeline and BioDefense detection system (Nature, 2022; Cell Genomics, 2023).
HITLAB conducted an independent evaluation of 48 sources across science, regulation, commerce, and national security, concluding that IndyGeneUS Bio represents a credible and timely solution to the global genomic diversity gap.